89 related articles for article (PubMed ID: 11478274)
1. [Effect of the preparation Wobe-Mugos E on parameters of the antioxidant defence system and morphofunctional erythrocyte status in patients with chronic obstructive bronchitis].
Kolomoiets' MIu; Kovalenko SV; Todoriko LD
Lik Sprava; 2000 Sep; (6):100-4. PubMed ID: 11478274
[TBL] [Abstract][Full Text] [Related]
2. [Wobe-Mugos: a proteolytic enzyme combination for tumor therapy. Documentation No. 7].
Schweiz Rundsch Med Prax; 1987 Dec; 76(51):1430-2. PubMed ID: 3326110
[No Abstract] [Full Text] [Related]
3. [Systemic enzyme therapy with the preparation Wobe-Mugos E in the combined treatment of lung cancer patients].
Smolanka II
Lik Sprava; 2000; (5):121-3. PubMed ID: 11031472
[TBL] [Abstract][Full Text] [Related]
4. [Application of systemic enzyme therapy in combined treatment of patients with pulmonary cancer and malignant thymoma].
Hanul VL; Smolanka II; Ponomar'ova OV
Klin Khir; 2000 Jun; (6):17-9. PubMed ID: 11288269
[TBL] [Abstract][Full Text] [Related]
5. Double-blind pilot-study on the efficacy of enzyme therapy in advanced colorectal cancer.
Popiela T; Kulig J; Kłek S; Wachol D; Bock PR; Hanisch J
Przegl Lek; 2000; 57 Suppl 5():142. PubMed ID: 11202281
[TBL] [Abstract][Full Text] [Related]
6. [The effect of the preparation Wobe-Mugos E on the functional and biochemical status of the kidneys in the polyuric stage of sublimate-induced nephropathy].
Rohovyĭ IuIe; Myslyts'kyĭ VF; Filipova LO; Shapovalov VP; Mahalias MV; Maĭkan RI; Chortyk IuB
Fiziol Zh (1994); 2000; 46(3):51-6. PubMed ID: 11059387
[TBL] [Abstract][Full Text] [Related]
7. The role of Wobe-Mugos in reducing acute sequele of radiation in head and neck cancers--a clinical phase-III randomized trial.
Kaul R; Mishra BK; Sutradar P; Choudhary V; Gujral MS
Indian J Cancer; 1999; 36(2-4):141-8. PubMed ID: 10921218
[TBL] [Abstract][Full Text] [Related]
8. [The use of enzymes in treating patients with malignant lymphoma with a large tumor mass].
Gubareva AA
Lik Sprava; 1998 Aug; (6):141-3. PubMed ID: 9844901
[TBL] [Abstract][Full Text] [Related]
9. Enzyme therapy in patients with advanced colorectal cancer.
Popiela T; Kulig J; Kłek S; Wachol D; Bock PR; Hanisch J
Przegl Lek; 2000; 57 Suppl 5():138-9. PubMed ID: 11202278
[No Abstract] [Full Text] [Related]
10. Efficacy of Wobe-Mugos E for reduction of oral mucositis after radiotherapy : results of a prospective, randomized, placebo-controlled, triple-blind phase III multicenter study.
Dörr W; Herrmann T;
Strahlenther Onkol; 2007 Mar; 183(3):121-7. PubMed ID: 17340069
[TBL] [Abstract][Full Text] [Related]
11. Polyenzyme preparation Wobe-Mugos inhibits growth of solid tumors and development of experimental metastases in mice.
Wald M; Závadová E; Poucková P; Zadinová M; Boubelik M
Life Sci; 1998; 62(3):PL43-8. PubMed ID: 9488106
[TBL] [Abstract][Full Text] [Related]
12. Local transrectal enzymatic treatment for chronic nonbacterial prostatitis and prostatodynia: initial clinical experience.
Kerbl K; Zisch R
Tech Urol; 2000 Mar; 6(1):22-5. PubMed ID: 10708143
[TBL] [Abstract][Full Text] [Related]
13. [The favorable effect of hydrolytic enzymes in the treatment of immunocytomas and plasmacytomas].
Sakalová A; Mikulecký M; Holománová D; Langner D; Ransberger K; Stauder G; Mistrík M; Gazová S; Chabronová I; Benzová M
Vnitr Lek; 1992 Sep; 38(9):921-9. PubMed ID: 1481392
[TBL] [Abstract][Full Text] [Related]
14. [Enzyme therapy--an alternative in treatment of herpes zoster. A controlled study of 192 patients].
Billigmann P
Fortschr Med; 1995 Feb; 113(4):43-8. PubMed ID: 7713467
[TBL] [Abstract][Full Text] [Related]
15. [Use of WOBE-MUGOS E for prevention and correction of experimental doxorubicin side-effects].
Todor IN; Solianik GI; Iurchenko OV; Shpilevaia SI; Luk'ianova NIu; Trindiak VP; Kunskaia LN; Ponomareva OV; Terzov AI; Kulik GI; Chekhun VF
Lik Sprava; 2001; (3):116-21. PubMed ID: 11559997
[TBL] [Abstract][Full Text] [Related]
16. [Modification of liver parameters by adjuvant administration of proteolytic enzymes following chemotherapy in patients with ovarian carcinoma].
Lahousen M
Wien Med Wochenschr; 1995; 145(24):663-8. PubMed ID: 8585220
[TBL] [Abstract][Full Text] [Related]
17. Micronuclei evaluation of reduction in neoadjuvant chemotherapy related acute toxicity in locally advanced lung cancer: an indian experience.
Bahl A; Chander S; Julka PK; Rath GK; Sharma DN; Kumar A; Nair O
J Assoc Physicians India; 2006 Mar; 54():191-5. PubMed ID: 16800343
[TBL] [Abstract][Full Text] [Related]
18. Does prophylactic treatment with proteolytic enzymes reduce acute toxicity of adjuvant pelvic irradiation? Results of a double-blind randomized trial.
Martin T; Uhder K; Kurek R; Roeddiger S; Schneider L; Vogt HG; Heyd R; Zamboglou N
Radiother Oncol; 2002 Oct; 65(1):17-22. PubMed ID: 12413670
[TBL] [Abstract][Full Text] [Related]
19. [The efficacy of the multienzyme preparation Wobe-Mugos E in lymphoproliferative diseases].
Kolomoiets' MIu; Antofiĭchuk MP
Lik Sprava; 1999 Jun; (4):150-4. PubMed ID: 10476670
[TBL] [Abstract][Full Text] [Related]
20. [Effects of proteolytic enzyme therapy with Wobe Mugos against chemotherapy-induced toxicity in breast cancer patients - results of a pilot study].
Petru E; Stranz B; Petru C
Wien Med Wochenschr; 2010 Nov; 160(19-20):513-6. PubMed ID: 20972712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
